Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 65-77 , February 2009

The role of the endocannabinoid system in liver diseases

References 

  1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006;58:389–462
  2. Mallat A, Lotersztajn S. Endocannabinoids and liver disease. Endocannabinoids and their receptors in the liver. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;294:G9–G12
  3. Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. Endocannabinoid involvement in obesity and hepatic steatosis. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;294:G1101–G1104
  4. Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;294:G357–G362
  5. Pacher P, Gao B. Endocannabinoids and liver disease. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;294:G850–G854
  6. Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. Journal of Neuroendocrinology. 2008;20(Suppl. 1):47–52
  7. Sherlock Sheila. Nutritional and metabolic liver disease. In:  Sherlock Sheila editors. Disease of the liver and biliary system. 8th edn.. Blackwell Scientific Publications; 1989;p. 470–500
  8. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (Baltimore, Md.). 2005;42:44–52
  9. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clinics in Liver Disease. 2007;11:1–16
  10. Sampath H, Miyazaki M, Dobrzyn A, et al. Stearoyl CoA-desaturase-1 mediates the pro-lipogenic effect of dietary saturated fat. The Journal of Biological Chemistry 207(282): 2483–2493.
  11. Lin J, Yang R, Tarr PT, et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1betacoactivation of SREBP. Cell. 2005;120:261–273
  12. Osei-Hyiaman D, Depetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation. 2005;115:1298–1305
  13. Osei-Hyiaman Liu J, Zhou L, Godlewsky G, et al. The Journal of Clinical Investigation. 2008;118:3160–3169
  14. Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (Baltimore, Md.). 2007;46:122–129
  15. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver International. 2006;27:215–219
  16. Deveaux V, Ichitogani Y, Texeira-Clerc F, et al. CB2 receptor antagonism reduces diet-induced obesity, insulin-resistance and hepatic steatosis. Hepatology (Baltimore, Md.). 2007;46:308A
  17. Reuben A. Alcohol and the liver. Current Opinion in Gastroenterology. 2008;24:328–338
  18. Jeong W, Osei-Hyaman D, Park O, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metabolism. 2008;7:227–235
  19. Castera L, Chouteau P, Hezode C, et al. Hepatitis C virus-induced hepatocellular steatosis. The American Journal of Gastroenterology. 2005;100:711–715
  20. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (Baltimore, Md.). 2001;33:1358–1364
  21. Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter?. Gut. 2006;55:123–130
  22. Hézode C, Roudot-Thoraval F, Zafrani ES, et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Journal of Viral Hepatitis. 2004;11:455–458
  23. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642
  24. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology (Baltimore, Md.). 2006;43:1177–1186
  25. Hézode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008;134:432–439
  26. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clinics in Liver Disease. 2006;10:459–479
  27. Siegmund SV, Shwabe RF. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2008;294:G357–G362
  28. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology (Baltimore, Md.). 2005;42:63–71
  29. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine. 2006;12:671–676
  30. Julien B, Grenard P, Texeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–755
  31. Siegmund SV, Uchinami H, Osawa Y, et al. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology (Baltimore, Md.). 2005;41:1085–1095
  32. Siegmund SV, Qian T, De Minicis S, et al. The endocannabinoid 2-arachidonyl glycerol induces death of hepatic stellate cells via mitochondrial oxygen species. The FASEB Journal. 2007;21:2798–2806
  33. Munoz-Luque J, Ros J, Fernandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. The Journal of Pharmacology and Experimental Therapeutics. 2008;324:475–483
  34. Domenicali M, Caraceni P, Pertosa AM, et al. Effect of cannabinoid CB1-receptor antagonism on ascitic decompensation of rats with preascitic cirrhosis. Journal of Hepatology. 2008;48(Suppl. 2):S38
  35. Bosch J, Berzigotti A, Garcia-Pagan JC, et al. The management of portal hypertension: rational basis, available treatments and future options. Journal of Hepatology. 2008;48(Suppl. 1):S68–S92
  36. Yang YY, Lin HC, Huang YT, et al. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2005;290:G328–G334
  37. Yang YY, Lin HC, Huang YT, et al. Effect of chronic CB1 receptor antagonism on livers of rats with biliary cirrhosis. Clinical Science. 2007;112:533–542
  38. Kowalsky HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. The Journal of Clinical Investigation. 1953;32:1025–1033
  39. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (Baltimore, Md.). 1988;8:1151–1157
  40. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (Baltimore, Md.). 2002;35:478–491
  41. Sacerdoti D, Abraham NG, Oyekan AO, et al. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. The Journal of Pharmacology and Experimental Therapeutics. 2004;308:636–643
  42. Oberti F, Sogni P, Cailmail S, et al. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology (Baltimore, Md.). 1993;18:621–627
  43. Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Medicine. 2001;7:827–832
  44. Ros J, Claria J, To-Figueras J, et al. A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122:85–93
  45. Maccarrone M, Bari M, Battista N, et al. Endocannabinoid degradation, endotoxic shock and inflammation. Current Drug Targets. Inflammation and Allergy. 2002;1:53–63
  46. Garcia N, Járai Z, Mirshahi F, et al. Systemic and portal hemodynamic effects of anandamide. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2001;280:G14–G20
  47. Ralevic V, Kendall DA, Randall MD, et al. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sciences. 2002;71:2577–2594
  48. Domenicali M, Ros J, Fernández-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut. 2005;54:522–527
  49. Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. British Journal of Pharmacology. 2006;149:898–908
  50. Fernández-Rodriguez CM, Romero J, Petros TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver International. 2004;24:477–483
  51. Lo Verme J, La Rana G, Russo R, et al. The search for the palmitoylethanolamide receptor. Life Sciences. 2005;77:1685–1698
  52. Re G, Barbero R, Miolo A, et al. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Veterinary Journal (London, England : 1997). 2007;173:21–30
  53. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nature Clinical Practice. Gastroenterology & Hepatology. 2006;3:329–337
  54. Zambruni A, Trevisani F, Caraceni P, et al. Cardiac electrophysiological abnormalities in patients with cirrhosis. Journal of Hepatology. 2006;44:994–1002
  55. Gaskari SE, Liu H, Moezi L, et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. British Journal of Pharmacology. 2005;146:315–323
  56. Batkai S, Mukhopadhyay P, Harvey-White J, et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. American Journal of Physiology. Heart and Circulatory Physiology. 2007;293:H1689–H1695
  57. Huguet C, Gavelli A, Chieco A, et al. Liver ischemia for hepatic resection: where is the limit?. Surgery. 1992;111:251–259
  58. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Seminars in Liver Disease. 2001;21:105–113
  59. Strasberg SM, Howard TK, Molmenti EP, et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology (Baltimore, Md.). 1994;20:829–838
  60. Jaeschke H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2006;290:G1083–G1088
  61. Kurabayashi M, Takeyoshi I, Yoshinari D, et al. 2-arachidonylglycerol increases in ischemia-reperfusion injury of rat liver. Journal of Investigative Surgery. 2005;18:25–31
  62. Batkai S, Osei-Hyiaman D, Pan H, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia-reperfusion injury. The FASEB Journal. 2007;21:1781–2000
  63. Rajesh M, Pan H, Mukhopadhyay P, et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia-reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. Journal of Leukocyte Biology. 2007;82:1382–1389
  64. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischemia-reperfusion injury and preconditioning. British Journal of Pharmacology. 2008;153:252–262
  65. Marshall JC, Nathens AB. The gut in critical illness: evidence from human studies. Shock. 1996;6:S10–S16
  66. Colletti LM, Green M. Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous lipopolysaccaride which also increases hepatic TNF production in vivo and in vitro. Shock (Augusta, Ga.). 2001;16:312–319
  67. Kojima Y, Suzuki S, Tsuchiya Y, et al. Regulation of pro-inflammatory and anti-inflammatory cytokine responses by Kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia. Transplant International. 2003;16:231–240
  68. Jaeschke H, Bajt ML. Critical role of CXC chemokines in endotoxemic liver injury in mice. Journal of Leukocyte Biology. 2004;76:1089–1090
  69. Di Marzo V. targeting the endocannabinoid system: to enhance or reduce?. Nature Reviews. Drug Discovery. 2008;7:438–455

PII: S1521-690X(08)00137-1

doi: 10.1016/j.beem.2008.10.009

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 65-77 , February 2009

Article Tools

* Image Usage & Resolution